Recombinant Mouse Leukocyte surface antigen CD47 (Cd47)

What is the basic structure of mouse CD47 and how does it compare to human CD47?

Mouse CD47, like its human counterpart, is an integral membrane protein belonging to the immunoglobulin superfamily. It consists of an extracellular domain (ECD) with a single Ig-like domain, five membrane-spanning regions with short intervening loops, and a cytoplasmic tail. Human CD47 comprises a 123 amino acid extracellular domain with similar structural organization . The mouse and human CD47 proteins share approximately 63% amino acid sequence identity in the N-terminal ECD region .

This structural homology is important for researchers working with mouse models, though the CD47-SIRPα interaction demonstrates species specificity that must be considered when translating findings between species. This species-specific interaction has significant implications for xenotransplantation studies and when evaluating therapeutic approaches targeting the CD47-SIRPα axis.

What are the primary signaling pathways associated with mouse CD47?

Mouse CD47 engages in several key signaling pathways:

The interaction between CD47 and SIRPα represents the canonical "don't eat me" signaling pathway, which prevents phagocytosis of CD47-expressing cells. This pathway has significant implications for immune evasion in cancer and plays crucial roles in normal tissue homeostasis . The interaction between CD47 and thrombospondin-1 influences various cellular processes including angiogenesis and cell death, making it relevant for vascular biology research.

How does mouse CD47 regulate normal tissue homeostasis?

Mouse CD47 contributes to tissue homeostasis through several mechanisms:

• Self-recognition: CD47 serves as a "marker of self" that prevents clearance of healthy cells by phagocytes.

• Mesenchymal progenitor regulation: CD47 promotes mesenchymal stem cell (MSC) proliferation, particularly during stress or injury states . In CD47-null mice, MSC colony expansion and proliferation are reduced, with decreased formation of large colonies (>100 ALP positive cells) compared to wild-type .

• Vascular homeostasis: CD47 influences endothelial cell density and function. CD47-null mice exhibit increased endothelial cell density in peripheral callus regions during bone healing .

• Tissue repair: CD47 regulates the early phases of injury response. In fracture models, CD47-null mice show delayed callus formation at day 10 post-fracture, with reductions in bone volume and bone volume fraction . This suggests CD47 plays a role in the early cellular responses to tissue damage.

These findings indicate that CD47 is not merely an immune checkpoint molecule but serves broader functions in tissue maintenance and repair processes.

What are the optimal methods for producing recombinant mouse CD47 for research applications?

Production of high-quality recombinant mouse CD47 typically follows these methodological approaches:

• Expression system selection: Most researchers use mammalian expression systems (HEK293 or CHO cells) for mouse CD47 production to ensure proper post-translational modifications, especially glycosylation patterns that may be important for function.

• Construct design considerations:

  • Full-length vs. extracellular domain only: For many applications, the extracellular domain fused to an Fc tag (similar to human CD47-Fc chimera) provides sufficient biological activity

  • Codon optimization for the expression system

  • Inclusion of appropriate purification tags (His, Fc, etc.)

• Purification protocol:

  • Affinity chromatography (typically Protein A for Fc-tagged constructs)

  • Size exclusion chromatography to remove aggregates

  • Endotoxin removal steps for in vivo applications

• Quality control assessments:

  • SDS-PAGE and Western blot for purity and identity verification

  • Functional binding assays to confirm interaction with SIRPα

  • Endotoxin testing for in vivo applications

For researchers requiring carrier-free preparations (without BSA or other carrier proteins), special attention should be paid to protein stability during storage, as carrier-free preparations may be less stable over time .

What are the critical considerations when designing CD47 knockout or knockdown experiments in mice?

When designing CD47 knockout or knockdown studies, researchers should consider:

• Model selection:

  • Global knockout: Useful for understanding systemic effects but may confound tissue-specific functions

  • Conditional knockout: Preferred for tissue-specific studies to avoid developmental compensation

  • Inducible knockout: Valuable for temporal control, especially when studying acute vs. chronic effects

• Sex-specific considerations:
  Two-way ANOVA analysis of CD47-null mice has revealed both interaction and sex-based effects in fracture healing models. Female mice show greater fibrous tissue content and percent cartilage regardless of genotype, with reductions in percent bone and marrow . Most phenotypic variation, particularly at early time points (day 10), appears to be primarily driven by genotype differences rather than sex .

• Control selection:

  • Littermate controls are essential to minimize genetic background effects

  • Include both wild-type and heterozygous animals when possible

  • Control for potential off-target effects in CRISPR-generated models

• Phenotypic assessment timeline:
  Studies show that CD47-null mice exhibit delayed fracture healing at day 10 post-injury, but these differences largely disappear by day 20 . This temporal dynamic highlights the importance of multiple assessment timepoints when characterizing CD47 knockout phenotypes.

• Complementary approaches:

  • Pair genetic models with pharmacological inhibition

  • Consider rescue experiments to confirm phenotype specificity

  • Use cell-specific markers to identify affected cell populations

What are the recommended protocols for assessing CD47 expression in mouse tissues?

For immunostaining approaches, researchers should be aware that CD47 antibody epitope accessibility may be affected by tissue fixation methods. For optimal results:

• Use fresh frozen sections when possible for maximal epitope preservation

• If using fixed tissues, validate antigen retrieval methods specifically for CD47

• Include appropriate positive and negative controls (especially CD47-null tissues)

• Consider dual staining with multiple CD47 antibodies recognizing different epitopes

How can mouse CD47 models be used to investigate therapeutic targeting strategies?

Mouse models provide valuable platforms for investigating CD47-targeting therapeutic approaches:

• Antibody-based therapies:

  • Anti-CD47 blocking antibodies can be tested for efficacy in disrupting CD47-SIRPα interactions

  • Bispecific antibodies targeting both CD47 and tumor-specific antigens can be evaluated for increased specificity

  • Protease-activated antibody technologies like SGN-CD47M show promise for selective tumor targeting with reduced systemic toxicity

• Genetic engineering approaches:

  • Humanized SIRPα mouse models using piggyBac, CRISPR/Cas9, or TALEN-mediated BAC transgenesis enable testing of human-specific anti-CD47 therapeutics

  • These models are particularly valuable since CD47-SIRPα interactions are species-specific

• Combination therapy assessment:

  • Mouse models can evaluate synergistic effects between CD47 blockade and conventional checkpoint inhibitors

  • CD47 blockade in combination with chemotherapy or radiation can be studied for enhanced efficacy

• Toxicity and biodistribution studies:

  • Mouse models allow for assessment of on-target/off-tumor effects

  • Tissue-specific conditional knockouts help distinguish therapeutic vs. adverse effects

Researchers should note that while mouse models are invaluable, the species-specific nature of CD47-SIRPα interactions means that humanized models may be required for translational studies of human-targeted therapeutics.

What are the molecular mechanisms through which CD47 influences mesenchymal progenitor cell function?

Recent research has revealed several mechanisms by which CD47 regulates mesenchymal progenitor cells:

• Proliferative capacity regulation:
  CD47-null mesenchymal progenitor cells show reduced proliferation compared to wild-type cells. This is evidenced by:

  • Decreased formation of large colonies (>100 ALP-positive cells) in culture

  • Reduced MTT measurements at days 6 and 10 post-harvest, indicating lower metabolic activity

  • Decreased BrdU incorporation, particularly at day 1 post-passage

• Contact inhibition modulation:
  CD47 appears to influence cell-cell contact regulation in mesenchymal progenitor cells, potentially through:

  • Interaction with integrin signaling pathways

  • Modulation of cell adhesion molecule expression

  • Regulation of mechanosensitive signaling cascades

• Stress response mediation:
  CD47 appears particularly important during stress conditions:

  • No difference in bone marrow counts is observed prior to plating between WT and CD47-null mice

  • Differences in proliferation become apparent during culture or injury states

  • This suggests CD47 plays a key role in stress response pathways in mesenchymal progenitors

• Differentiation pathway effects:
  CD47 influences the balance of differentiation pathways, as evidenced by:

  • Altered callus composition in CD47-null fracture models (increased fibrous tissue and cartilage, decreased bone and marrow)

  • Changes in the expression of lineage-specific markers

These mechanisms highlight CD47's complex role beyond immune evasion, positioning it as a key regulator of mesenchymal progenitor function during tissue repair and regeneration.

How does CD47 function differ between tumor and normal tissues in mouse models?

CD47 exhibits distinct functional profiles in tumor versus normal tissues in mouse models:

• Expression level differences:

  • Tumors typically show elevated CD47 expression compared to corresponding normal tissues

  • This upregulation correlates with activation of several oncogenic pathways

  • In colorectal cancer models, CD47-high expression is associated with mutations in TP53, KMT2C, and CIC, while showing lower frequencies of KRAS mutation

• Immune microenvironment interactions:

  • CD47 expression in tumors is associated with an immune-engaged tumor microenvironment

  • In CD47-high colorectal cancer subtypes, there are higher frequencies of CMS1 (17.9% vs 14.5%) and CMS4 (40.1% vs 26.8%) molecular subtypes

  • These subtypes are characterized by distinct immune infiltration patterns

• Vascular effects:

  • CD47 disruption increases vascularization in non-bone tissues

  • In tumor contexts, this may influence tumor angiogenesis and delivery of therapeutics

  • CD47-null mice show higher density of EMCN+ and CD31+ endothelial cells in peripheral callus regions

• Proliferative consequences:

  • While CD47 promotes normal mesenchymal progenitor proliferation, its role in tumor cells may differ

  • CD47 blockade can have direct antiproliferative effects on certain tumor types

  • The proliferative impact of CD47 targeting varies depending on tumor type and molecular context

Understanding these contextual differences is crucial for developing targeted therapeutic approaches that disrupt CD47's tumor-promoting functions while minimizing impact on normal tissue function.

What are common pitfalls in CD47 functional assays and how can they be addressed?

Researchers working with CD47 functional assays should be aware of these common challenges:

• Species-specific interaction issues:

  • Human CD47 does not bind mouse SIRPα effectively and vice versa

  • Solution: Use species-matched proteins or validated cross-reactive reagents

  • Consider humanized SIRPα mouse models for translational studies

• Inconsistent phagocytosis assay results:

  • Variability in macrophage activation status

  • Differences in target cell:macrophage ratios

  • Solution: Standardize macrophage sources and activation protocols

  • Include positive controls (CD47 blocking antibodies) and negative controls

• Antibody epitope accessibility problems:

  • CD47 epitopes may be masked by interaction partners

  • Solution: Use multiple antibody clones targeting different epitopes

  • Consider mild fixation methods that preserve epitope accessibility

• Background from Fc receptor binding:

  • When using CD47-Fc fusion proteins or antibodies

  • Solution: Include appropriate Fc blocking reagents

  • Use F(ab')2 fragments when possible for blocking experiments

• Variability in CD47 knockout phenotypes:

  • Sex-dependent effects that influence experimental outcomes

  • Temporal dynamics that change with development or injury stage

  • Solution: Analyze males and females separately

  • Include multiple timepoints in healing or developmental studies

How can researchers resolve contradictory findings between in vitro and in vivo CD47 studies?

When faced with discrepancies between in vitro and in vivo CD47 research findings, consider these methodological approaches:

• Context-dependent signaling analysis:

  • CD47 functions differently depending on microenvironmental factors

  • Approach: Systematically compare signaling pathway activation between in vitro cultures and tissue samples

  • Use phospho-specific antibodies to assess pathway activation status

• Model complexity considerations:

  • In vitro models may lack critical cell-cell interactions present in vivo

  • Approach: Employ co-culture systems or organoids that better recapitulate tissue complexity

  • Consider ex vivo tissue slice cultures as intermediate models

• Temporal dynamics evaluation:

  • In vivo phenotypes may be temporary or compensated over time

  • Approach: Conduct time-course studies both in vitro and in vivo

  • As observed in fracture healing models, CD47-null phenotypes at day 10 largely disappear by day 20

• Genetic background influences:

  • Strain-specific modifiers may affect in vivo but not in vitro findings

  • Approach: Test multiple genetic backgrounds or use congenic strains

  • Consider F2 intercrosses to identify modifier loci

• Experimental validation hierarchy:

  • Approach: Establish a systematic validation pipeline:

    1. Confirm antibody specificity on CD47-null tissues/cells

    2. Validate phenotypes with multiple knockout/knockdown approaches

    3. Perform rescue experiments to confirm specificity

    4. Evaluate phenotypes in multiple cellular/tissue contexts

How is CD47 involved in the bone repair process and what are the implications for regenerative medicine?

Recent research has revealed CD47's unexpected role in bone repair processes:

• Temporal regulation of callus formation:

  • CD47-null mice exhibit delayed callus formation at day 10 post-fracture

  • μCT analysis shows reductions in bone volume and bone volume fraction in CD47-null mice

  • Interestingly, the bone formed in the absence of CD47 shows higher average tissue mineral density (TMD) at day 10

• Cell-specific effects during repair:

  • Mesenchymal progenitor proliferation is reduced in CD47-null conditions

  • EdU incorporation studies show decreased cell proliferation in CD47-null fracture callus at day 7 post-fracture

  • Endothelial cell density increases in the peripheral callus region of CD47-null mice

• Sex-specific considerations in bone repair:

  • Female mice show greater fibrous tissue content and percent cartilage regardless of CD47 status

  • Female mice exhibit reductions in percent bone and marrow during early repair

  • These sex-related differences largely equalize by day 20 post-fracture

• Therapeutic implications:

  • Temporary CD47 blockade might enhance vascularization while allowing later stage proliferation

  • Sex-specific treatment approaches may be warranted based on differential responses

  • Targeting CD47 could potentially enhance endothelial cell contribution to tissue repair

These findings suggest complex and time-dependent roles for CD47 in tissue repair processes, with important implications for regenerative medicine applications targeting the CD47 pathway.

What are the latest findings regarding CD47's role in immunotherapy resistance mechanisms?

Emerging research highlights several mechanisms through which CD47 contributes to immunotherapy resistance:

• Molecular resistance pathways:

  • CD47-high tumors show distinct mutation profiles, including higher frequencies of mutations in TP53, KMT2C, and CIC genes

  • CD47-high colorectal tumors exhibit molecular subtypes (CMS1 and CMS4) associated with distinct immune infiltration patterns

  • These molecular signatures may predict response to CD47-targeted therapies

• Adaptive resistance mechanisms:

  • Following CD47 blockade, tumors may upregulate alternative "don't eat me" signals

  • CD24, PD-L1, and MHC-I have been implicated in compensatory pathways

  • These compensatory mechanisms suggest rational combination therapy approaches

• Tumor microenvironment influences:

  • Hypoxia upregulates CD47 expression, potentially limiting efficacy in poorly vascularized tumors

  • Myeloid composition of the tumor microenvironment affects response to CD47 blockade

  • Tumor-associated macrophage polarization status impacts phagocytic capacity following CD47 blockade

• Novel targeting strategies:

  • Protease-activated antibody technologies like SGN-CD47M enable selective tumor targeting

  • Bispecific antibodies targeting CD47 and tumor-specific antigens show enhanced specificity

  • These approaches may overcome limitations of first-generation CD47-targeting strategies

Understanding these resistance mechanisms is crucial for developing effective combination strategies and identifying biomarkers that predict response to CD47-targeted therapies.

How does CD47 interact with the damage-associated molecular pattern (DAMP) signaling pathway in tissue repair?

Recent findings suggest important interactions between CD47 and DAMP signaling pathways:

• CD47 and DAMP expression correlation:

  • In colorectal cancer studies, CD47 expression levels correlate with DAMPs signature scores

  • This signature includes CALR, HMGB1, ANXA1, HSPAA1, HSPA1A, and CXCL10

  • The correlation suggests functional interaction between CD47 signaling and DAMP pathways

• Mechanistic interactions:

  • CD47 may regulate the release of DAMPs following cellular stress or damage

  • Alternatively, DAMPs may influence CD47 expression or signaling

  • These interactions appear particularly relevant during tissue injury responses

• Tissue repair implications:

  • During fracture healing, CD47 disruption affects early cellular responses

  • This may involve altered DAMP signaling that influences recruitment of repair-associated cells

  • The temporal dynamics of healing in CD47-null mice suggest early DAMP-mediated effects

• Therapeutic targeting potential:

  • Modulating both CD47 and DAMP pathways might enhance tissue repair

  • Timing of interventions would be critical given the temporal dynamics observed in repair processes

  • Combined biomarkers of CD47 and DAMP pathway activation might predict repair outcomes

Further research is needed to fully elucidate the molecular mechanisms connecting CD47 and DAMP signaling pathways, but these interactions represent promising targets for enhancing tissue repair processes.

What are the most promising translational applications of mouse CD47 research?

Mouse CD47 research has revealed several promising translational applications:

• Cancer immunotherapy optimization:

  • Development of next-generation CD47-targeting approaches with improved specificity

  • Identification of biomarkers predicting response to CD47-targeted therapies

  • Rational combination strategies based on molecular subtypes and resistance mechanisms

• Regenerative medicine applications:

  • Temporary CD47 blockade to enhance vascularization during tissue repair

  • Stage-specific CD47 modulation to optimize healing processes

  • Sex-specific treatment approaches based on differential responses to CD47 disruption

• Autoimmune disease interventions:

  • CD47 agonists to reduce inappropriate phagocytosis in autoimmune conditions

  • Targeting CD47-thrombospondin interactions to modulate inflammatory responses

  • Cell-specific delivery strategies to limit off-target effects

• Xenotransplantation advances:

  • Genetic engineering of donor tissues to express human CD47

  • This approach could help overcome species barriers in xenotransplantation

  • Humanized CD47/SIRPα mouse models provide valuable platforms for testing these approaches

These translational applications highlight the diverse potential of CD47-targeted interventions across multiple disease contexts and therapeutic modalities.

What key knowledge gaps remain in our understanding of mouse CD47 biology?

Despite significant advances, several important knowledge gaps remain in mouse CD47 biology:

• Isoform-specific functions:

  • The functional significance of CD47 splice variants remains poorly understood

  • Cell type-specific expression patterns of different isoforms need further characterization

  • Potential differences in signaling pathway activation between isoforms require investigation

• Non-canonical signaling pathways:

  • Beyond SIRPα and thrombospondin-1, CD47 likely engages additional binding partners

  • The complete CD47 interactome in different tissues and cell types remains to be fully mapped

  • Context-dependent signaling outcomes need systematic characterization

• Developmental roles:

  • CD47's functions during embryonic and postnatal development are incompletely understood

  • Potential compensation mechanisms in developmental contexts require further study

  • Stage-specific requirements for CD47 signaling need investigation

• Metabolic influences:

  • How CD47 signaling interfaces with cellular metabolism remains largely unexplored

  • Potential metabolic differences in CD47-null tissues may contribute to observed phenotypes

  • Metabolomic profiling of CD47-deficient models could reveal new functional insights

Addressing these knowledge gaps will require integrative approaches combining genetic models, systems biology, and advanced imaging techniques to fully elucidate CD47's multifaceted biological roles.

What technological advances will drive the next phase of CD47 research?

Several emerging technologies are poised to advance CD47 research:

• Single-cell multi-omics approaches:

  • Single-cell RNA/ATAC-seq to map CD47 expression and regulation at cellular resolution

  • Spatial transcriptomics to understand CD47 expression in tissue microenvironmental contexts

  • These approaches will help resolve cell type-specific CD47 functions in complex tissues

• Advanced protein interaction mapping:

  • Proximity labeling techniques (BioID, APEX) to map the CD47 interactome in living cells

  • Hydrogen-deuterium exchange mass spectrometry to characterize dynamic interaction interfaces

  • These methods will help identify novel CD47 binding partners and signaling connections

• Intravital imaging advances:

  • Multiphoton microscopy with genetically encoded sensors to visualize CD47 signaling in vivo

  • Light-sheet microscopy for 3D visualization of CD47-expressing cells during tissue repair

  • These imaging approaches will help resolve the temporal and spatial dynamics of CD47 function

• CRISPR-based functional genomics:

  • Genome-wide CRISPR screens to identify synthetic lethal interactions with CD47

  • CRISPRi/a approaches for precise modulation of CD47 expression

  • CRISPR base editing for introduction of specific CD47 mutations

  • These genomic tools will enable more precise dissection of CD47 function

• Computational modeling approaches:

  • Systems biology models integrating CD47 signaling networks

  • Machine learning to predict CD47 pathway activation from multi-omics data

  • These computational approaches will help integrate diverse data types and generate testable hypotheses